Arcutis Biotherapeutics, Inc. ARQT
We take great care to ensure that the data presented and summarized in this overview for Arcutis Biotherapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARQT
View all-
Jennison Associates LLC11.7MShares$144 Million0.07% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$135 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$132 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$108 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$106 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.96MShares$85.7 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X06.88MShares$84.7 Million0.39% of portfolio
-
State Street Corp Boston, MA5.64MShares$69.4 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.25MShares$52.3 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.78MShares$46.5 Million0.0% of portfolio
Latest Institutional Activity in ARQT
Top Purchases
Top Sells
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Insider Transactions at ARQT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-5.82%
|
$120,000
$12.51 P/Share
|
|
Nov 30
2024
|
Todd Franklin Watanabe Director |
BUY
Open market or private purchase
|
Direct |
2,038
+0.24%
|
$14,266
$7.11 P/Share
|
|
Nov 30
2024
|
Masaru Matsuda Officer |
BUY
Open market or private purchase
|
Direct |
1,657
+0.88%
|
$11,599
$7.11 P/Share
|
|
Nov 30
2024
|
Larry Todd Edwards Officer |
BUY
Open market or private purchase
|
Direct |
1,093
+0.79%
|
$7,651
$7.11 P/Share
|
|
Nov 22
2024
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
16,023
-11.07%
|
$160,230
$10.14 P/Share
|
|
Nov 22
2024
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,023
+9.97%
|
-
|
|
Nov 19
2024
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
1,775
-0.97%
|
$15,975
$9.68 P/Share
|
|
Nov 18
2024
|
Masaru Matsuda Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,875
+2.59%
|
-
|
|
Nov 15
2024
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
100
-0.08%
|
$1,000
$10.03 P/Share
|
|
Nov 15
2024
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.08%
|
-
|
|
Nov 14
2024
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
69,126
-20.39%
|
$691,260
$10.29 P/Share
|
|
Nov 14
2024
|
Patrick Burnett Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,377
+11.11%
|
-
|
|
Nov 11
2024
|
Terrie Curran Director |
SELL
Open market or private sale
|
Direct |
8,687
-46.14%
|
$86,870
$10.85 P/Share
|
|
Nov 04
2024
|
Patrick Burnett Officer |
SELL
Open market or private sale
|
Direct |
15,441
-7.92%
|
$123,528
$8.68 P/Share
|
|
Nov 04
2024
|
Todd Franklin Watanabe Director |
SELL
Open market or private sale
|
Direct |
13,871
-1.64%
|
$110,968
$8.68 P/Share
|
|
Nov 04
2024
|
Masaru Matsuda Officer |
SELL
Open market or private sale
|
Direct |
5,015
-2.74%
|
$40,120
$8.68 P/Share
|
|
Nov 01
2024
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-5.5%
|
$80,000
$8.65 P/Share
|
|
Oct 02
2024
|
Larry Todd Edwards Officer |
SELL
Open market or private sale
|
Direct |
3,725
-2.65%
|
$37,250
$10.01 P/Share
|
|
Oct 01
2024
|
Howard G. Welgus Director |
SELL
Open market or private sale
|
Direct |
10,000
-5.21%
|
$90,000
$9.26 P/Share
|
|
Sep 24
2024
|
David Joseph Topper Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,626
-6.84%
|
$104,634
$9.48 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.24M shares |
|---|---|
| Open market or private purchase | 33.8K shares |
| Bona fide gift | 13.1K shares |
| Exercise of conversion of derivative security | 84.1K shares |
| Bona fide gift | 13.1K shares |
|---|---|
| Open market or private sale | 396K shares |